Binding pockets are small, concave regions on the surface of a protein where other molecules attach and trigger a biological response. They are defined by their shape, their chemical environment, and their ability to selectively recognize specific partners. Understanding what makes these pockets work is central to biology and drug design alike.
Shape and Size of Binding Pockets
Binding pockets are not flat surfaces. They are three-dimensional cavities, clefts, or grooves carved into a protein’s structure. Most ligand-binding pockets fall in a volume range of roughly 100 to 1,000 cubic angstroms, though flexibility can shift that range considerably. The active site of HIV-1 protease, for example, can vary from about 853 to 1,566 cubic angstroms across different complexes with different inhibitor molecules.
The geometry of these pockets matters enormously. A pocket’s depth, curvature, and overall contour determine which molecules can physically fit inside. A shallow, wide pocket interacts with molecules very differently than a deep, narrow tunnel. These structural features are so important that drug researchers evaluate pocket depth, volume, and enclosure as key criteria when deciding whether a protein can be targeted by a drug at all.
Chemical Composition Sets Them Apart
The amino acid residues lining a binding pocket are chemically distinct from the rest of the protein surface. Certain amino acids, particularly arginine and histidine, appear in binding sites far more often than elsewhere on the protein. These residues can carry electrical charges and form strong interactions with incoming molecules. Histidine is especially versatile because it can switch between charged and uncharged states depending on pH, making it useful for catalysis and molecular recognition.
Residues in binding pockets also tend to be highly connected within the protein’s internal communication network. They interact directly, or through very few intermediates, with a large number of other residues in the structure. When researchers mutate these residues, the protein typically loses activity but actually becomes more structurally stable, suggesting the pocket region exists in a somewhat strained, “ready to act” state.
How Pockets Recognize the Right Molecule
Binding pockets are selective because they rely on two layers of complementarity. The first is shape: the pocket and its binding partner must fit together geometrically, like puzzle pieces. The second is chemical compatibility. The pocket’s electrostatic properties, its pattern of positive and negative charges, hydrogen bond donors and acceptors, and hydrophobic patches must align with corresponding features on the ligand. A molecule that fits the shape but clashes chemically will bind weakly or not at all.
This dual requirement explains why even proteins with similar-looking pockets can bind very different molecules, and why unrelated proteins sometimes bind the same molecule. Researchers have found that unrelated binding sites often contain similar small structural motifs that recognize specific chemical fragments in ligands, regardless of what the rest of the ligand looks like.
Lock-and-Key Versus Induced Fit
Two models describe how a molecule enters a binding pocket. The older one, proposed by Emil Fischer in 1894, is the lock-and-key model: the pocket and the ligand have perfectly complementary shapes from the start, and the ligand slots in without either partner changing shape. This model held for about 60 years.
In the 1950s, Daniel Koshland proposed the induced-fit model. He argued that when the correct substrate binds, it causes the amino acids in the pocket to shift position, bringing catalytic groups into the precise orientation needed for the reaction. Koshland compared it to a hand sliding into a glove: the glove changes shape to accommodate the hand. A wrong molecule might enter the pocket but would fail to trigger the necessary rearrangement, so no reaction would occur.
The induced-fit model did not replace lock-and-key entirely. Instead, it expanded the idea. The core principle of complementarity remained, but proteins were now understood to be flexible rather than rigid. Most real binding events involve some degree of both: an initial shape match followed by fine-tuning as the pocket adjusts around the ligand.
Orthosteric Versus Allosteric Pockets
Not all binding pockets do the same job. An orthosteric pocket is the protein’s main active site, where the natural substrate or signaling molecule binds. An allosteric pocket sits somewhere else on the protein surface, away from the active site.
When a molecule binds the orthosteric site, it directly competes with the protein’s natural partner. This can shut down the protein’s activity entirely. Allosteric binding works differently. A molecule binding at an allosteric site sends a ripple of structural changes through the protein, like a wave propagating across the surface, until it reaches the active site and reshapes it. This can either boost or dampen the protein’s function without fully blocking it.
This distinction has real consequences for drug design. Orthosteric drugs need to match the active site’s shape and chemistry precisely enough to outcompete the body’s own molecules. Allosteric drugs don’t need to win that competition. They can exert their effect even while the natural ligand is bound at the active site, and they tend to modulate activity rather than switching it completely off. That makes allosteric drugs attractive when fine-tuning, rather than silencing, a protein’s behavior is the goal.
The Role of Water Inside the Pocket
Before a ligand arrives, binding pockets are not empty. They are filled with ordered water molecules that form hydrogen bonds with the pocket’s walls and contribute to the protein’s stability. When a ligand binds, it displaces some or all of these water molecules. Releasing trapped water into the surrounding solution increases entropy (disorder), which can provide a significant boost to binding strength.
However, this process is not always favorable. If a water molecule is tightly bound and makes strong interactions with the pocket, removing it costs energy. The incoming ligand must form new interactions that more than compensate for losing that water molecule, or the overall binding affinity will actually decrease. Research on kinase inhibitors has shown that the change in binding affinity from a chemical modification correlates with how easily the displaced water molecule can be removed. Displacing a loosely held water can improve affinity by several kilocalories per mole, while displacing a tightly held one can make binding worse.
This means that drug designers cannot simply assume that filling every corner of a pocket will improve a drug. Each water molecule in the pocket has its own energetic cost of removal, and getting this calculation wrong can weaken a drug candidate rather than strengthen it.
What Makes a Pocket “Druggable”
Not every binding pocket on a protein can be targeted by a drug. Pharmacologists use the term “druggability” to describe whether a pocket has the right combination of features to bind a small drug-like molecule tightly and specifically. The criteria include pocket volume, depth, degree of enclosure, hydrophobicity (how water-repelling the interior is), the proportion of charged residues, and the availability of hydrogen bond donors and acceptors.
A druggable pocket is typically deep enough that a small molecule can bury itself inside, hydrophobic enough to favor the displacement of water, and enclosed enough to make extensive contact with the ligand on multiple sides. Shallow, flat, or highly polar pockets are generally harder to drug because small molecules struggle to form enough simultaneous interactions to bind tightly. Computational tools like SiteScore and DoGSiteScorer evaluate these properties automatically across a protein’s surface, helping researchers identify the most promising targets before any experiments begin.